Here’s a bold statement: Johnson & Johnson isn’t just meeting expectations—it’s blowing them out of the water, even as it navigates one of the most controversial moves in healthcare today. But here’s where it gets controversial: the company has struck a deal with the U.S. government to slash drug prices for Americans, a move that’s costing it hundreds of millions of dollars. Yet, despite this financial hit, J&J is forecasting 2026 profits that surpass Wall Street’s wildest estimates. How is this even possible? Let’s break it down.
On Wednesday, Johnson & Johnson revealed its 2026 sales and profit projections, which not only outpace analyst predictions but also account for the significant financial impact of its recent drug pricing agreement with the Trump administration. This deal, part of a broader initiative involving 16 major pharmaceutical companies, lowers U.S. drug prices in exchange for exemptions from Trump-imposed tariffs. And this is the part most people miss: even with this massive concession, J&J’s financial outlook remains remarkably robust.
Chief Financial Officer Joseph Wolk hinted at the scale of the sacrifice, stating, “We can’t disclose specific details, but it’s hundreds of millions of dollars.” Despite this, the company’s 2026 operational sales are projected between $99.5 billion and $100.5 billion, surpassing analysts’ estimates of $98.9 billion. Similarly, J&J expects full-year 2026 profits of $11.43 to $11.63 per share, slightly edging out the $11.45 per share analysts had forecast.
What’s driving this optimism? For starters, J&J’s fourth-quarter results were stellar, fueled by strong sales of its blood cancer therapy Darzalex, impressive growth in its psoriasis drug Tremfya, and resilience in its medical devices division. These successes come at a time when the company is battling multiple headwinds, including tariff uncertainties and rising competition from biosimilars for its blockbuster psoriasis drug Stelara. Here’s the kicker: Stelara sales declined more than expected, yet J&J’s overall growth remains unwavering.
Wolk highlighted this resilience, noting, “If you just take Stelara out of that mix, that portfolio is growing 14%, 15%. Those are the products we’re going to rely on for the next couple of years and the balance of this decade.” On an adjusted basis, the healthcare giant reported quarterly earnings of $6 billion, or $2.46 per share, topping Wall Street’s $2.44 per share expectation. Quarterly revenue also exceeded forecasts, hitting $24.56 billion compared to the expected $24.16 billion.
Digging deeper, J&J’s Innovative Medicine division—its largest—saw a 10% sales increase to $15.76 billion, beating estimates of $15.37 billion. Meanwhile, its devices business grew 7.5% to $8.8 billion. These numbers paint a picture of a company not just surviving but thriving in the face of adversity.
But here’s the controversial question: Is J&J’s willingness to cut drug prices a genuine commitment to affordability, or a strategic move to secure tariff exemptions and maintain its market dominance? And as the company faces ongoing legal battles over its talc products—with a court-appointed special master recently recommending expert testimony linking talc to ovarian cancer—how will these challenges impact its long-term reputation and financial health?
What’s your take? Is J&J’s bold financial forecast a testament to its resilience, or is there more to the story? Let us know in the comments below—we’d love to hear your thoughts!
